Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...

The Industry is on the brink of a substantial surge, with the market size expected to reach USD 100 Million in 2023 and ...

In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Hindustan Unilever (HUL)- the country's leading FMCG player will come up with its Q2 earnings on October 23, 2024 (Wednesday) ...

GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger ...

Earnings before interest, tax, depreciation, and amortisation (Ebitda) is likely to remain flat at Rs 3,698.7 crore on an ...

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...